The National Health Service (NHS) in the UK has announced a significant expansion of its childhood immunisation programme, planning to vaccinate all babies against chickenpox starting next year. This move, hailed by experts as a potential 'life saver,' marks the biggest change to the programme in a decade and is expected to make chickenpox a problem of the past. Ministers have stated that the vaccine, which is reported to be 98 percent effective, will save millions of school and nursery sick days, thereby alleviating the burden on parents who often scramble for childcare or miss work.

While chickenpox is often considered a mild disease that most children catch in childhood, it can lead to serious complications. These include pneumonia, brain inflammation (encephalitis), and bacterial infections, which can be fatal in rare cases. Annually, hundreds of babies are hospitalised due to severe symptoms, and approximately 25 people die from the illness in England. It also poses risks during pregnancy, affecting both mother and baby. The virus is highly contagious, with each infected person estimated to pass it on to ten others, making it more transmissible than the common cold or flu.

From January next year, the chickenpox, or varicella, vaccine will be incorporated into a new Measles, Mumps, Rubella, and Varicella (MMRV) jab, replacing the existing MMR vaccine. This live vaccine contains a weakened version of the chickenpox virus and is therefore not recommended for individuals with compromised immune systems due to conditions like HIV or treatments such as chemotherapy. The introduction of routine varicella vaccination brings the UK into line with other countries, including Germany, Canada, Australia, and the US, which already offer it.

Regarding effectiveness, about nine out of ten children develop immunity after a single chickenpox jab, with this figure increasing for those who receive both doses. However, the NHS notes that immunity may wane over time, protecting only about three-quarters of vaccinated teenagers and adults. In contrast, natural infection typically leads to lifelong immunity. Experts consistently affirm the vaccine's safety. Common, mild, and short-lasting side effects include a sore arm, a mild rash, and a high temperature, consistent with other vaccines. Serious allergic reactions are rare, occurring in about one in a million people. Millions of doses have been administered globally, with no evidence of increased health risks. While the MMRV jab carries a small seizure risk (estimated at one additional seizure per 2,300 doses), the Joint Committee on Vaccination and Immunisation (JCVI) has deemed this 'very small increased risk' not a clinical concern.

The delayed rollout in Britain was previously due to concerns that childhood vaccination might lead to a problematic rise in shingles, a condition also caused by the varicella-zoster virus. There were also worries that individuals not exposed to the virus as children might develop more severe chickenpox as adults. However, new evidence has consistently disproved these theories, leading health officials to change their position in 2023, with the JCVI recommending the jab after determining that its benefits outweighed the risks. Countries already offering the vaccine have reported significant drops in chickenpox cases and hospitalisations.

The vaccine will be offered to over half a million children annually in two doses, administered at 12 months and 18 months of age. Health officials are also considering a catch-up programme for millions more under-fives, though it is not anticipated to be available to older children on the NHS. This shift to the new MMRV vaccine coincides with a revised schedule for the second MMR dose, which will now be given at 18 months for children born from July last year onwards, rather than at three years and four months. The chickenpox vaccine is currently available for free on the NHS to specific groups, such as those in regular close contact with immunocompromised individuals, and privately costs around £150.

The benefits of this programme are clear. Minister of State for Care, Stephen Kinnock, emphasized the vaccine's role in protecting against four serious diseases—measles, mumps, rubella, and chickenpox—giving parents peace of mind and supporting children's health and education. The Department of Health and Social Care (DHSC) estimates that chickenpox costs the UK economy approximately £24 million annually in lost income and productivity, largely due to parents taking time off work. The vaccine rollout is also expected to save the NHS £15 million each year in treatment costs. This initiative is part of the government's 'Plan for Change' mission to ensure every child has the best start in life, preventing illness rather than solely treating it.

Despite this advancement, the NHS faces challenges in increasing childhood jab uptake. Recent data revealed that none of the routine childhood vaccines in England met the 95 percent uptake target in 2024/25, with MMR vaccination levels at their lowest in over a decade. Parents are urged to bring their children forward for their jabs as soon as they are invited.

Common chickenpox symptoms include an itchy, spotty rash, often accompanied by a high temperature, aches, and loss of appetite. Individuals are advised to stay home from school, nursery, or work until all spots have scabbed over, typically five days after the rash appears. While it usually clears within a couple of weeks, severe complications like bacterial skin infections, sepsis, brain swelling, stroke, and even death can occur in rare instances.